Thursday, July 16, 2026

11:15 AM - 1:15 PM

---

Details

A substantial body of research has highlighted the role of inflammation in all stages of atherosclerosis. Advances in multiomics techniques have unveiled the intricate complexity of immune cells across various cardiovascular diseases (CVD). Additionally, large-scale clinical trials have validated the inflammatory hypothesis in humans, providing solid evidence that targeting inflammation is an effective strategy for treating CVD. This research led to a significant milestone in June 2023, when the FDA approved colchicine as the first anti-inflammatory treatment for the secondary prevention of CVD. The goal of this symposium is to offer a comprehensive overview of the latest knowledge on immune mechanisms in CVD and their potential as therapeutic targets. To achieve this, we have invited internationally renowned scientists to share their insights. We propose hosting this symposium on behalf of the IUPHAR Immunopharmacology Committee, aimed at engaging scientists and clinicians interested in the intersection of pharmacology, immunology, and cardiovascular science.

---

Session chair